You are here: Industry Insights > NICE

News List

A NICE yes for latest immunotherapy Bavencio pharmaphorum
March 06, 2018
NICE has recommended Merck KGaA and Pfizer’s Bavencio in previously treated metastatic Merkel Cell Carcinoma, a rare and aggressive form of skin cancer.
NICE Positive Recommendation Supports Use of Bavencio (Avelumab) for Treatment of Adults in England, firstwordpharma
March 02, 2018
NICE has issued a Final Appraisal Determination (FAD) that recommends avelumab for treating adults with metastatic Merkel Cell Carcinoma (mMCC).2
NICE approves Perjeta for routine use on NHS pharmafile
February 02, 2018
NICE has given the nod to Roche’s Perjeta for routine first-line use, alongside Herceptin and chemotherapy, in patients with HER2-positive breast cancer.
NICE urges curbing the use of antibiotics for sore throats pharmafile
January 29, 2018
In a study published by the BMJ a few years ago, it was found that antibiotics were prescribed in 60% of cases when a patient visited a doctor regarding a sore throat.
NICE backs wider use of MSD’s Simponi pharmatimes
January 11, 2018
Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.
NICE to reassess Pfizer’s leukaemia drug Besponsa pharmatimes
January 03, 2018
The National Institute for Health and Care Excellence will reassess Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia.
NICE to take another look at Pfizer’s leukaemia drug pharmafile
January 03, 2018
Back in August of 2017, NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds and the pharma giant was not best pleased.
NICE rejects Roche’s Tecentriq for pre-treated urothelial cancer pharmatimes
December 25, 2017
Cost regulators for NHS treatments in England and Wales have turned down Roche’s Tecentriq for patients who have already received prior treatment for metastatic urothelial cancer.
NICE recommends routine access to beta interferon drug for MS europeanpharmaceuticalreview
December 22, 2017
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
NICE turns down rare skin disease implant pharmatimes
December 21, 2017
The National Institute for Health and Care Excellence has rejected Clinuvel UK’s afamelanotide for treating erythropoietic protoporphyria (EPP) in preliminary guidelines deeming it far too expensive for NHS use.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page